Frontiers in Biomedicine: Pr Diether Lambrechts
13.03.2025 12:30 – 13:30
«Single-cell profiling of the tumor microenvironment during checkpoint immunotherapy»
Cancer immunotherapy using immune-checkpoint blockade (ICB) has created a paradigm shift in the treatment of advanced-stage cancers. In terms of lives saved and person-years restored, these therapies promise to be more significant than any other form of cancer treatment. However, one of the major limitations of ICB is that it provides durable clinical responses only in a fraction of patients. Single-cell (spatial) technologies have been exceptionally instrumental in highlighting how checkpoint immunotherapy works in some patients, and why not in other patients. During his talk, Pr Lambrechts will highlight how T-cells respond differently to these therapies, which surrounding microenvironments are needed to provide durable responses and where in the tumor tissue these T-cells need to be located. He will also highlight how responding T-cells and the tumor antigens that they recognize can be characterized, and how this information can be harnessed to develop novel synergistic therapies that can be combined with approved checkpoint inhibitors.
Lieu
Bâtiment: CMU
Auditoire Müller
Organisé par
Département de pathologie et immunologieDécanat Faculté de médecine
Evénements de la Faculté de médecine
Centre de recherche translationnelle en oncohématologie (CRTOH)
Intervenant-e-s
Pr Diether LAMBRECHTS, Science Director, Center for Cancer Biology, VIB, Leuven & Full Professor, Department for Human Genetics, University of Leuven, Belgiumentrée libre
Classement
Catégorie: Frontiers in Biomedicine
Mots clés: Faculté de médecine, Frontiers in Biomedicine
Fichiers joints
![]() | afficheA3_FIB_Lambrechts.pdf | 173.5 Kb |